Last reviewed · How we verify
Faculdade de Ciências Médicas da Santa Casa de São Paulo — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| sugammadex ED90 | sugammadex ED90 | marketed | Selective relaxant binding agent | Rocuronium and vecuronium (steroidal neuromuscular blocking agents) | Anesthesia |
Therapeutic area mix
- Anesthesia · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Korea University Guro Hospital · 1 shared drug class
- Merck Sharp & Dohme LLC · 1 shared drug class
- Regina Elena Cancer Institute · 1 shared drug class
- University Health Network, Toronto · 1 shared drug class
- University of California, Irvine · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Faculdade de Ciências Médicas da Santa Casa de São Paulo:
- Faculdade de Ciências Médicas da Santa Casa de São Paulo pipeline updates — RSS
- Faculdade de Ciências Médicas da Santa Casa de São Paulo pipeline updates — Atom
- Faculdade de Ciências Médicas da Santa Casa de São Paulo pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Faculdade de Ciências Médicas da Santa Casa de São Paulo — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/faculdade-de-ci-ncias-m-dicas-da-santa-casa-de-s-o-paulo. Accessed 2026-05-18.